1 Endothelin-1(1 ± 31) (ET-1(1 ± 31); 0.25 to 4 nmol kg
Introduction
Endothelin-1 (ET-1) is a 21 amino acid peptide which exhibits potent vasoconstrictor and hypertensive eects, alongside various other physiological actions (for reviews, see Rubanyi & Poloko, 1994; Miyauchi & Masaki, 1999) . This peptide is generated from the 38 amino acid precursor, big ET-1, through cleavage of the Trp 21 -Val 22 bond by an ETconverting enzyme (ECE) and produces its eects via stimulation of two speci®c G-protein-coupled receptors, namely ET A and ET B . Until recently, the ET peptide family was believed to encompass only two additional members, ET-2 and ET-3, both highly homologous and formed via the same analogous pathways as ET-1. Nevertheless, Nakano et al. (1997) reported that human mast cell chymase cleaves the Tyr 31 -Gly 32 bond of big ET-1 to yield ET-1(1 ± 31), a novel potent contractile peptide of both vascular and non-vascular smooth muscle tissues. It has been suggested that ET-1(1 ± 31) must be converted to ET-1 via the neutral endopeptidase 24rat trachea (Nakano et al., 1997) and aorta, porcine coronary arteries (Kishi et al., 1998) or human coronary artery smooth muscle cells (Inui et al., 1999) . Like ET-1, ET-1(1 ± 31) can also stimulate vascular smooth muscle cell proliferation via a PKC-dependent ERK1/2 activation-mediated mechanism, as well as nitric oxide release from endothelial cells (Yoshizumi et al., 1998; Niwa et al., 2000) . Some studies have shown that ET-1(1 ± 31) acts as a selective ET A receptor agonist in rat cultured zona glomerulosa cells (Mazzocchi et al., 2000; Rebuat et al., 2001) . Furthermore, others found that its smooth muscle contractile eects on the porcine coronary artery and nitric oxide-releasing actions on endothelial cells are amenable to blockade by selective ET A and ET B receptor antagonists, respectively Niwa et al., 2000) .
Curiously, since the discovery of ET-1(1 ± 31), there has been no report on its in vivo pharmacology. We have therefore attempted to characterize, in well-documented pharmacological models, the pressor, bronchoconstrictive and pulmonary eicosanoid-releasing properties of this peptide in the guinea-pig (D'OrleÂ ans- Juste et al., 1991 Juste et al., , 1994 Gratton et al., 1995; Lewis et al., 1999) . In these models, we have shown that the pressor eects of ET-1 were solely mediated by ET A receptors, whereas both the enhancement of pulmonary insuation pressure (PIP) in vivo and the thromboxane A 2 (TxA 2 ) release from guinea-pig isolated perfused lungs were entirely dependent on ET B receptor activation (D'OrleÂ ans-Juste et al., 1994; Lewis et al., 1999) .
Moreover, several groups including our own have previously characterized a phosphoramidon-sensitive ECEdependent pharmacological eect of big ET-1 and -2 in the anaesthetized guinea-pig (Fukuroda et al., 1990; Pons et al., 1992; Gratton et al., 1995) . In the human bronchial smooth muscle, the intracellular calcium-increasing properties of ET-1(1 ± 31) are abolished by both phosphoramidon (PR) and thiorphan (TP), suggesting that the peptide must be hydrolyzed by NEP to ET-1 in vitro (Hayasaki-Kajiwara et al., 1999) .
In view of the above considerations, we have addressed in the present study the putative contribution of the phosphoramidon-sensitive ECE- (Xu et al., 1994) and NEP-mediated conversion pathways, as well as the endothelin receptors involved in the pharmacological eects of ET-1(1 ± 31) in vivo, in the anaesthetised guinea-pig. We also examined the potential involvement of eicosanoids in the pulmonary eects of ET-1(1 ± 31) in vivo, as well as its ability to trigger release of these mediators from isolated perfused lungs.
Methods

In vivo experiments
Duncan ± Hartley guinea-pigs (250 ± 350 g; Charles River, StConstant, QueÂ bec, Canada) of either sex were anaesthetized with ketamine/xylazine (87/13 mg kg 71 , i.m.). As in vivo experiments lasted no longer than 120 min, maintenance doses of anaesthetics were not required. Polyethylene catheters (PE-50) were inserted into the left external jugular vein and right carotid artery for drug administration and recording of mean arterial blood pressure (MAP) and heart rate, respectively. Another cannula (PE-240) was then inserted into the trachea following tracheostomy to facilitate respiration. A blood pressure analyser (Micro-Med, Louisville, KY, U.S.A.) was used to monitor MAP and heart rate. The data were recorded at ®xed 60 s time intervals throughout the entire experiment by an automated computer data acquisition system (Digi-Med ). For recording of bronchoconstrictor responses, PIP was monitored continuously with a pressure transducer (Statham, Model P23AC) connected to a side arm of the tracheal cannula and coupled to a Grass polygraph (Model 7D), according to the method of Konzett & RoÈ ssler (1940) . After 45 min of stabilization, the pharmacological responses to the various agonists were monitored for at least 45 min following their administration.
For sake of clarity, the biphasic pressor response to the highest dose of ET-1(1 ± 31) was identi®ed as having two distinct phases: a ®rst phase with a rapid onset (within the ®rst 10 min following injection) and a second phase with a slower onset (10 ± 45 min following injection) and more sustained. ), or the corresponding vehicle. All pretreatments were given 5 min before peptide injection, except indomethacin and CGS 35066, which were administered 30 min beforehand. In all cases, the eects of the inhibitors and antagonists were determined against the maximal MAP and PIP responses. The vehicles used (phosphate-buered saline (PBS), PBS-DMSO 5 ± 10%, PBS-Trizma base (0.2 M) 50% or NaHCO 3 (0.25 M)) were systematically tested and found not to alter either basal or agonist-induced changes in MAP or PIP values. Table 1 describes the dierent agonists, inhibitors and antagonists used in this study as well as the appropriate references for their respective dose ranges.
Measurements of eicosanoids from isolated perfused guinea-pig lungs
Guinea-pigs with the above-mentioned speci®cations were killed by cervical dislocation. Following thoracotomy, the pulmonary artery was cannulated for perfusion of the pulmonary circulation with a heparinized (100 units ml ) with an oxygenated (95% O 2 , 5% CO 2 ) Krebs' solution. The lungs were left to stabilize for 45 min before a 3 min i.a. infusion of either ET-1 (5 nM), ET-1(1 ± 31) (5 or 50 nM) or big ET-1 (100 nM). In a second series of experiments, one of the agonists was administered following infusion of either endothelin receptor antagonists, BQ-123 (1 mM, 15 min) or BQ-788 (5 or 10 nM, 15 min), or the NEP inhibitor, TP (25 mM, 60 min). Concentrations of the dierent drugs were chosen according to a previously reported study (D'OrleÂ ansJuste et al., 1994). The euent from the lungs was collected (1 min samples) before, during and after infusion of the various agents. The samples were stored at 7208C until determination of their levels of stable hydrolytic metabolites of prostacyclin (6-Keto-prostaglandin F 1a (6-Keto-PGF 1a )) and (TxA 2 ) (thromboxane B 2 (TxB 2 )) by radioimmunoassay (Salmon, 1978) . Ihara et al., 1992) was synthesized in our laboratory by Dr Witold Neugebauer. ET-1(1 ± 31) and PR were purchased from Peptides International (Louisville, KY, U.S.A.). CGS 35066 ((S)-3-Dibenzofuran-3-yl-2-(phosphomethylamino)-proprionic acid) was kindly provided by Dr A. Jeng (Novartis, Summit, NJ, U.S.A.). TP, indomethacin, 6-Keto-PGF 1a , TxB 2 6-Keto-PGF 1a and TxB 2 antisera were obtained from Sigma (St Louis, MO, U.S.A.). Tritiated 6-Keto-PGF 1a and TxB 2 were purchased from Amersham (Oakville, Ontario, Canada). The 6-Keto-PGF 1a antiserum has 100% cross-reactivity with authentic 6-Keto-PGF 1a , 23% with prostaglandin E 1 (PGE 1 ), 4% with prostaglandin E 2 (PGE 2 ), 7% with prostaglandin F 2a (PGF 2a ) and less than 1% with TxB 2 .
The TxB 2 antiserum has a 100% cross-reactivity with authentic TxB 2 , less than 2% cross-reactivity with prostaglandin D 2 (PGD 2 ) and PGF 1a , and less than 0.1% crossreactivity with 6-Keto-PGF 1a , PGE 1 and PGE 2 . Both 6-Keto-PGF 1a and TxB 2 radioimmunoassays have a detection limit of 0.4 ng ml
71
. The eicosanoid antisera used in the present study did not cross-react with any of the agonists or inhibitors used. ET-1(1 ± 31) and TP were dissolved in PBS ± DMSO 10%, BQ-788, BQ-123 in PBS ± DMSO 5%, indomethacin in PBS-Trizma base (0.2 M) 50% and CGS 35066 in NaHCO 3 (0.25 M). All other agents were dissolved in PBS.
Data analysis
Results are shown as mean+s.e.mean for n experiments. Since the various responses to ET-1 studied were very poorly reversible, animals or perfused organs were not used as their own controls for the in vivo and in vitro experiments with inhibitors or antagonists. Statistical comparisons were made using the Student's t-test or by ANOVA followed by the Dunnett's test for multiple comparisons where speci®ed. Dierences in which P50.05 were considered signi®cant.
Ethics
The care of animals and all of the research protocols conformed to the guiding principles for animal experimentation, as enunciated by the Canadian Council on Animal Care and approved by the Ethical Committee on Animal Research of the UniversiteÂ de Sherbrooke.
Results
Effects of ET-1(1 ± 31) on MAP and PIP
The average basal MAP and PIP values established in the anaesthetized guinea-pig were determined at 47.8+0.6 mmHg and 3.0+0.1 mmHg, respectively (n=140). ) and big ET-1 ). Characteristically, ET-1(1 ± 31) causes a biphasic change in MAP comprised of an early ®rst phase pressor eect, which is followed by a much more sustained response (second phase) (Figure 1a) . Furthermore, ET-1 induces a transient ( Figure 1b ) and big ET-1 a sustained (Figure 1c ) increase in MAP in a monophasic fashion. On the other hand, ET-1(1 ± 31), ET-1 and big ET-1 all induced monophasic increases in PIP (Figure 2) .
In another series of experiments, the maximal responses of ET-1(1 ± 31) and ET-1 at increasing doses were used to construct dose-response curves. Those curves represented in Figure 3 con®rm that ET-1(1 ± 31) is as potent as ET-1 to induce an initial increase in MAP. In contrast, ET-1(1 ± 31) induces a more sustained Phase 2 pressor response only at the highest dose used in the present study. Furthermore, ET-1(1 ± 31) is less potent than ET-1 to induce PIP increases. Higher doses of ET-1 (2.5 nmol kg
71
) and ET-1(1 ± 31) (5 nmol kg 71 ) induced death within less than 15 min of administration (n=2 for each).
This particular biphasic response to ET-1(1 ± 31) (4 nmol kg 71 ) has been compared to ET-1 and big ET-1 (1 and 5 nmol kg 71 , respectively) for the following in vivo studies.
Contribution of NEP and ECE in changes in MAP and PIP induced by ET-1(1 ± 31) Phosphoramidon (5 and 10 mg kg 71 ), a dual ECE/NEP inhibitor, reduced in a dose-dependent fashion both the ®rst and second phases of the pressor response to ET-1(1 ± 31) and the monophasic pressor response to big ET-1 (5 nmol kg 71 ) (Figure 4a, b) . In contrast, the selective ECE inhibitor, CGS 35066 (1 mg kg 71 ), did not reduce the ®rst phase yet signi®cantly inhibited the second phase of the pressor response to ET-1(1 ± 31), as well as the pressor response to big ET-1 (Figure 4a, b) . Thiorphan (0.25 and 2.5 mg kg 71 ) was without eect on the responses to ET-1(1 ± 31) and big ET-1 (Figure 4a, b) . In a last series of control experiments, the pressor eect of ET-1 (1 nmol kg 71 ) was not altered by either phosphoramidon, thiorphan nor CGS 35066 ( Figure  4c ). Figure 5 illustrates that phosphoramidon (5 and 10 mg kg ) (c) in the anaesthetized guinea-pig. Each point represents the mean+s.e.mean of 13, 10 and 6 experiments for ET-1(1 ± 31), ET-1 and big ET-1, respectively. *P50.05 relative to baseline value using the ANOVA followed by the Dunnett's test. ) (c) in the anaesthetized guinea-pig. Each point represents the mean+s.e.mean of 13, 10 and 6 experiments for ET-1(1 ± 31), ET-1 and big ET-1, respectively. *P50.05 relative to baseline value using the ANOVA followed by the Dunnett's test.
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Contribution of ET A and ET B receptors towards the pressor and PIP-increasing effects of ET-1(1 ± 31)
The second phase of the pressor response to ET-1(1 ± 31) (4 nmol kg 71 ), but not its ®rst phase nor its eects on PIP, was markedly reduced by the selective ET A receptor antagonist BQ-123 at 2.5 mg kg 71 (Figure 6a ). Furthermore the same antagonist also reduced the haemodynamic response to ET-1 (by less than 40% however) (Figure 6a ). In contrast, the selective ET B receptor antagonist BQ-788 (0.25 mg kg 71 ) was without eect on the pressor response to ET-1(1 ± 31). Interestingly, co-administration of both antagonists reversed the blockade of ET-1(1 ± 31) induced pressor response aorded by the sole administration of BQ-123 (Figure 6a ). On the other hand, the selective ET B receptor antagonist alone partially blocked the PIP increases induced by ET-1(1 ± 31) and more eciently the response to ET-1. Interestingly, co-administration of both antagonists is necessary to abolish the PIP increases triggered by ET-1(1 ± 31) (Figure 6b ).
Contribution of eicosanoids to the changes in MAP and PIP induced by ET-1(1 ± 31)
In another series of experiments, indomethacin (10 or 20 mg kg 71 , i.v.) failed to inhibit the transient (®rst phase) or sustained (second phase) pressor eects induced by ET-1(1 ± 31) or the response to ET-1 (Figure 7a) . As a matter of fact, the lower dose of indomethacin actually potentiated the ®rst phase of the increase in MAP induced by that peptide (Figure 7a ). In contrast, the cyclo-oxygenase inhibitor reduced by more than 50% the increase in PIP triggered by ET-1(1 ± 31) and abolished that of ET-1 (Figure 7b ).
Role of ET A and ET B receptors as well as of NEP in the eicosanoid-releasing properties of ET-1(1 ± 31)
In a series of in vitro experiments, ET-1(1 ± 31) was found to trigger the release of both TxB 2 and 6-Keto-PGF 1a , albeit at a potency 10-fold lower than that of ET-1 (Figure 8a, b) . Furthermore, TP (25 mM) fully abrogated the eicosanoid- ) (c), in the anaesthetized guinea-pig. Each bar represents the mean+s.e.mean of n experiments as indicated in brackets. *P50.05 relative to corresponding control value using the ANOVA followed by the Dunnett's test.
releasing eects of ET-1(1 ± 31) and also big ET-1 in the guinea-pig perfused lung (Figure 8c,d) . We have previously shown (D'OrleÂ ans-Juste et al., 1991) that phosphoramidon abolishes the release of TxB 2 , as well as that of 6-Keto-PGF 1a triggered by big ET-1, in the same preparation.
Finally, a 15 min pre-treatment with BQ-123 (1 mM) did not aect the release of TxB 2 nor that of 6-Keto-PGF 1a triggered by ET-1(1 ± 31) or ET-1 (Figure 9 ). In contrast, BQ-788 (5 and 10 nM) signi®cantly reduced in a concentrationdependent fashion the release of both eicosanoids induced by ET-1(1 ± 31) or ET-1 (Figure 9 ).
Discussion
The results of the current study show that exogenous ET-1(1 ± 31), a new member of the ET family formed by alternative cleavage of big ET-1 by mast cell chymase (Nakano et al., 1997) , induces dose-dependent increases in MAP and PIP in the anaesthetized guinea-pig. Moreover, we have found that both these in vivo eects of ET-1(1 ± 31) appear to depend, to varying extents, on its processing by ECE and/or NEP and activation of ET A and/or ET B receptors and are either mediated or modulated by COXderived eicosanoids.
ET-1(1 ± 31) was found to cause, at higher doses (4 nmol kg 71 ), a biphasic pressor eect comprising an earlier (transient) ®rst phase followed by a delayed (sustained) second phase, allied to a monophasic increase in PIP in the ), in the anaesthetized guinea-pig. Each bar represents the mean+s.e.mean of n experiments as indicated in brackets. *P50.05 relative to corresponding control value using the ANOVA followed by the Dunnett's test. ) in the anaesthetized guinea-pig. The antagonists were administered i.v. either alone or in combination, 5 min prior to each agonist injection. Each bar represents the mean+s.e.mean of n experiments as indicated in brackets. *P50.05 relative to corresponding control value using the ANOVA followed by the Dunnett's test. ) in the anaesthetized guinea-pig. The cyclo-oxygenase inhibitor was administered i.v. 30 min prior to each agonist injection. Each bar represents the mean+s.e.mean of n experiments as indicated in brackets. *P50.05 relative to corresponding control value using the ANOVA followed by the Dunnett's test.
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In vivo pharmacology of ET-1(1 ± 31) J.-C. Honore Â et alguinea-pig. Although both ET-1(1 ± 31) and ET-1 are clearly equipotent (on a molar basis) at transiently increasing MAP, ET-1(1 ± 31) is about 4 ± 10 fold less potent than ET-1 at increasing PIP. Considering that the actions of ET-1(1 ± 31), unlike those of ET-1, are reduced by pretreatment with blockers of ECE and/or NEP (as will be discussed in more detail in the following paragraph), it seems likely that the former peptide must be processed enzymatically in order to act. We suggest that this biotransformation proceeds at a more eective rate in the systemic circulation to increase MAP (even if, ultimately, this may be found to occur in systemic extra-luminal vascular compartments), than in the pulmonary circulation (or in extravascular sites in the lungs) to raise PIP.
The pressor and PIP-increasing actions of ET-1(1 ± 31), like those of big ET-1, are both sensitive to blockade by phosphoramidon, a dual ECE/NEP inhibitor (Matsumura et al., 1990) . In contrast, we found that thiorphan, a selective NEP inhibitor (Noble et al., 1999) , exerted distinct in¯uences on ET-1(1 ± 31)-induced increases in MAP and PIP. Whereas thiorphan modestly reduced the magnitude of the second phase of the peptide's pressor eect, it markedly and dosedependently inhibited its eect on PIP. In addition, thiorphan also abolished the eicosanoid-releasing eect of ET-1(1 ± 31) in isolated perfused lungs. This later ®nding corroborates the report of Hayasaki-Kajiwara et al. (1999) , showing that ET-1(1 ± 31)-induced changes in intracellular calcium concentration in human cultured bronchial smooth muscle cells are sensitive to blockade by NEP inhibitors. Altogether, these results would favour the view that NEP plays a more important role than ECE in bringing about the pulmonary eects of ET-1(1 ± 31) (as well as in those of big ET-1), whereas the peptide's pressor eects seems to depend more on its conversion by ECE than NEP. Previous studies have also shown that the bronchoconstrictive eects of big ET-1 in the guinea-pig in vivo (Pons et al., 1992) , as well as its contractile eect in isolated parenchymal strips (Battistini et al., 1995; Lebel et al., 1996) involves its conversion by a NEP-mediated (i.e. thiorphan-sensitive) pathway.
Nonetheless, as phosphoramidon causes dual ECE/NEP blockade and thiorphan, by selectively blocking NEP, also protects ET-1 from degradation, it is dicult to draw ®rm conclusions regarding the relative contributions of both enzymes in ET-1(1 ± 31) conversion based solely on the dierential susceptibility of the peptide's eects to modi®ca-tion by either compound. We attempted to circumvent this problem by testing the in¯uence of a potent and selective ECE inhibitor, CGS 35066 , on the eects of ET-1(1 ± 31) (and ET-1) in vivo. This compound (at 1 mg kg
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) was found to selectively reduce, but by no means Figure 8 Eects of ET-1(1 ± 31) (5 or 50 nM), ET-1 (5 nM) and big ET-1 (100 nM) on the release of thromboxane B 2 (a and c) and 6-Keto-PGF 1a (b and d) from the guinea-pig isolated and perfused lung. c and d also show that the release of either eicosanoid triggered by ET-1(1 ± 31) or big ET-1 is abolished by prior incubation with thiorphan (TP, 25 mM). Each point represents the mean+s.e.mean of at least seven dierent experiments. P50.05 relative to corresponding control value using the Student's t-test.
abolish, both the second phase of the pressor response and the PIP-increasing eects of ET-1(1 ± 31), without modifying the eects of ET-1. These results thus con®rm signi®cant contributions of ECE towards the pressor and PIP-increasing eects of ET-1(1 ± 31). Unfortunately however, as the 100-fold selectivity of CGS 35066 towards inhibition of ECE over NEP, seen in vitro, is lost in vivo at doses higher than 1 mg kg 71 Trapani et al., 2000) , we were unable to accurately determine to what extent conversion of ET-1(1 ± 31) via the ECE pathway is responsible for the peptide's eects on MAP and PIP in the guinea-pig, relative to NEP.
On the other hand, with the use of selective antagonists for ET A and ET B receptors (BQ-123 and BQ-788, respectively), we demonstrated here that the sustained (second phase) pressor response to ET-1(1 ± 31) is solely dependent on ET A receptors. In contrast, the transient (®rst phase) pressor response to ET-1(1 ± 31) was unaected by the selective ET A antagonist, as well as by the selective ET B antagonist.
Considering that indomethacin potentiated the ®rst phase pressor response to ET-1(1 ± 31), we suggest that the peptide may transiently trigger the release of vasodilatatory eicosanoids in the systemic circulation, which in turn limit the ®rst phase of the pressor response. Indeed, we have previously demonstrated that vasodilatatory eicosanoids eectively modulate the pressor eects of ET-1 or selective ET B receptor agonists in the guinea-pig (Lewis et al., 1999) . In addition, the resistance of the transient pressor response to ET-1(1 ± 31) to inhibition by BQ-123 and the poor ecacy of the ET A antagonist against ET-1 as described in the current study, are in agreement with Noguchi et al. (1993) who observed similar results with ET-1 in the anaesthetized guinea-pig. Interestingly, in our hands, simultaneous blockade of both ET A and ET B receptors partially reversed the intensity of blockade of the second phase pressor response to ET-1(1 ± 31) seen with the ET A receptor antagonist alone. This particular result reveals that ET-1(1 ± 31) may also generate, via ET B receptor activation, endogeneous inhibitors of the sustained component (second phase) of its pressor action. We have previously shown that a similar phenomenon occurs with respect to the in¯uence of selective versus mixed (i.e. combined ET A /ET B receptor blockade) ET receptor antagonists against ET-1-induced vasoconstriction in the rabbit perfused kidney (Maurice et al., 1997) .
In contrast to the pressor eect of ET-1(1 ± 31), the PIP response predominantly involves the activation of ET B receptors, as it was reduced by about 45% by BQ-788, but was unaected by BQ-123. Here again, we wished to con®rm that the same receptor population responsible for the bronchoconstrictive properties of ET-1(1 ± 31) would also generate the release of thromboxane A 2 from the pulmonary circulation, as previously demonstrated for ET-1 (Lewis et Figure 9 In¯uence of BQ-123 (selective ET A receptor antagonist, 1 mM) and BQ-788 (selective ET B receptor antagonist, 5 and 10 nM) on the release of thromboxane B 2 (a and c) and 6-Keto-PGF 1a (b and d) induced by ET-1(1 ± 31) (50 nM, in a and b) or ET-1 (5 nM, c and d) in the guinea-pig isolated and perfused lung. Each point represents the mean+s.e.mean of at least seven dierent experiments. *P50.05 when compared to the corresponding control value using ANOVA followed by the Dunnett's test.
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In vivo pharmacology of ET-1(1 ± 31) J.-C. Honore Â et alal., 1999) . Our results clearly show that the eicosanoidreleasing properties of ET-1(1 ± 31) are solely dependent on the activation of ET B receptors in the isolated perfused lungs of the guinea-pig. On the other hand, unlike ET-1, ET-1(1 ± 31) seems to also trigger a residual bronchoconstrictive eect which depends on eicosanoids, as revealed by the signi®cant (about 50% of the total response) indomethacin-insensitive component of the PIP response. Interestingly, this ®nding, allied to the fact that the ET-1(1 ± 31)-induced increase in PIP was unaected by BQ-123 alone but abolished by coadministration of BQ-123 plus BQ-788, demonstrates that the ET A receptor-mediated component of the PIP response to this peptide only appears when the ET B receptor-mediated generation of COX-derived eicosanoids is blocked. The need to block both receptor types in order to fully abrogate ET-1-induced constriction in guinea-pig airways has been previously reported (Nagase et al., 1995) . Thus, both receptor types are involved in the bronchoconstrictive properties of ET-1(1 ± 31) in guinea-pig airways.
Previous studies have advocated that ET-1(1 ± 31) displays selectivity of action towards either ET A (Mazzocchi et al., 2000; Rebuat et al., 2001) or ET B receptors . Our ®ndings demonstrate, however, that both receptor types are implicated in the MAP and PIP increasing eects of this peptide in the guinea-pig in vivo. Rather, they add further support to the report of Goldie et al. (2000) , showing that ET-1(1 ± 31) contracts rat isolated airways via activation of both ET A and ET B receptors.
In summary, the current study, which to our knowledge is the ®rst on this peptide to be carried out in vivo, reports that ET-1(1 ± 31) displays signi®cant pressor and eicosanoiddependent bronchoconstrictive properties in the anaesthetized guinea-pig. Both ET A and ET B receptors are involved in these in vivo eects of the peptide, which also depend critically, but to varying extents, on conversion of ET-1(1 ± 31) to an active metabolite, most likely ET-1, but this remains to be con®rmed.
